Get more Mail & Guardian
Subscribe or Login

Should everyone be getting the HIV prevention pill as part of this new study?

More than 500 people have signed up since December to be part of the country’s largest HIV vaccine trial, but some experts are crying foul over what they say is unequal access to the HIV prevention pill among participants.

Researchers are testing what is likely the world’s best shot at an HIV vaccine in 15 sites across the country in a trial called HVTN 702. As part of the trial, about 5 000 participants will receive either a placebo or the vaccine, which contains artificial proteins created to “look” like HIV although they are not actually infectious. If the jab can trick participants’ bodies into developing a way to fight off HIV infection, it could ultimately cut people’s risk of contracting the virus by about half.

But only a portion of the several hundred people who have volunteered for the study are also getting the HIV prevention pill, also known as pre-exposure prophylaxis (PrEP).

PrEP can reduce a person’s risk of HIV infection by more than 90%, depending on how regularly it’s taken, studies have shown. PrEP is currently only freely available to sex workers in the public sector as well as a small number of other people as part of pilot projects, which will help the government to decide how to roll it out more broadly.

Only people in the HIV vaccine trial who live near these pilot projects are able to get PrEP for free. African Alliance for HIV Prevention founder Tian Johnson says that this unequal access to the drug is unfair and compromises study participants’ rights.

HIV prevention studies must comply with international ethical guidelines that require researchers to provide participants with HIV prevention information and services to reduce their risk of contracting the virus in their communities.

According to the United Nations Joint Programme on HIV and Aids (UNAids), people who volunteer for prevention trials should get counselling and “state-of-the-art HIV risk reduction methods”. But what this means in practice, beyond simply supplying condoms, often varies by study and depends on governments and resources, UNAids admits in a  2012 document.

In South Africa, HIV vaccine trial sites are not currently offering participants PrEP because rolling out the HIV prevention pill is yet to become a national policy.

Instead, trial cochair Linda-Gail Bekker says the trial refers people interested in PrEP to pilot projects, when possible, or to the private sector. A month’s course of PrEP costs about R263 at retailers such as Clicks, said Bekker, speaking at the national Aids conference in Durban last week.

“People who are able to access PrEP [through pilot projects] are lucky —luckier than those millions of other people in the country who aren’t near to [pilot sites]. This isn’t an issue for the vaccine sites to deal with — it’s an issue for the government.

“I think they [the government] are very seriously trying to weigh up how, when and to whom to offer PrEP. Given our health budget, it may mean careful redistribution of priorities,” Bekker explains.

Health department spokesperson Popo Maja maintains that the government is awaiting results from projects before deciding how to make PrEP more widely available, especially to young women who are at a high risk of HIV infection.

Keymanthri Moodley, the director of  Stellenbosch University’s Centre for Medical Ethics and Law, says that, although sites are working to ensure access to PrEP, the equal treatment of trial participants is crucial.

She explains: “It is important that participants in a clinical trial investigating a new prevention option are offered a standard of care that includes all proven prevention options. This prevention package should be accessible in the same manner at all trial sites to ensure that participants are treated fairly.”

According to Johnson, this package should include PrEP and cover people’s access to it even after the trial concludes. Meanwhile, he argues there is more than enough evidence to support PrEP becoming widely available in the public sector — a step Kenya took in March.

He explains: “Advocates, now more than ever, need to stand up in defence of science and what science teaches us. What it has taught is that PrEP works.

“As clinical trial sites continue the important work of finding answers to ending HIV, advocates must be vigilant and hold trial sites and networks to account to meaningfully think about what their standard of care looks like when it comes to prevention.

“While being guided by national policies on PrEP … trials would do well to engage advocates to explore opportunities to accelerate the national PrEP agenda.”

Subscribe for R500/year

Thanks for enjoying the Mail & Guardian, we’re proud of our 36 year history, throughout which we have delivered to readers the most important, unbiased stories in South Africa. Good journalism costs, though, and right from our very first edition we’ve relied on reader subscriptions to protect our independence.

Digital subscribers get access to all of our award-winning journalism, including premium features, as well as exclusive events, newsletters, webinars and the cryptic crossword. Click here to find out how to join them and get a 57% discount in your first year.

Nelisiwe Msomi
Nelisiwe Msomi

Nelisiwe Msomi is a Junior journalist at Bhekisisa. She holds a bachelors degree in journalism from the University of Johannesburg. 

Previously, Msomi was a volunteer member of the Ahmed Kathrada Foundation’s media team and started off her career as an intern at Bhekisisa.

She has an interest in how government policies affect the ordinary person walking on Johannesburg’s Nelson Mandela Bridge and hopes to one day find a solution to long 6 am clinic queues.

"I have always seen journalism as a means of making the world a better place. Being part of Bhekisisa allows me to do just that, especially through the practice of solution based journalism. I believe that the work we do as journalist paves the path for better service delivery in our continent," she says.

Related stories

WELCOME TO YOUR M&G

If you’re reading this, you clearly have great taste

If you haven’t already, you can subscribe to the Mail & Guardian for less than the cost of a cup of coffee a week, and get more great reads.

Already a subscriber? Sign in here

Advertising

Subscribers only

Basic web lessons for South Africa: Government hacks point to...

Recent cyberattacks at the department of justice and the space agency highlight the extent of our naïveté

If the inflation-driving supply strain in the US lasts, it...

In South Africa, a strong trade surplus, buoyed by robust commodity prices, will cushion our economy against pressure arising from US policy

More top stories

ANC unlikely to replace Joburg mayor Matongo before 1 Nov

A party source said the ANC in Johannesburg would most likely call on one of the mayoral committee members to stand in as mayor until the local elections

Ramaphosa hits the right notes as he urges Cosatu to...

Cosatu meets to deliberate on its support for the governing party in the upcoming local government elections

DA insists IEC favoured the ANC after Constitutional Court dismisses...

The apex court’s dismissal of the Democratic Alliance’s application to declare reopening candidate registration unlawful came as no surprise

‘Factional’ ANC Veterans League chastised by Motlanthe

ANC Limpopo leaders called on the election committee to change the candidate lists in favour of Ramaphosa faction days before Motlanthe’s report on factions in the party
Advertising

press releases

Loading latest Press Releases…
×